Poly Medicure Posts Stellar Q3 Results on Acquisitions, Lacks YoY Data

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Poly Medicure Posts Stellar Q3 Results on Acquisitions, Lacks YoY Data
Overview

Poly Medicure Limited reported robust sequential growth in Q3 FY26, with consolidated revenue soaring 185.37% QoQ to ₹11,886.15 lacs and PAT jumping 195.59% to ₹7,838.38 lacs. The company recognized an exceptional item of ₹680.40 lacs. While acquisitions of Pendracare group and Medistream SA are progressing, year-on-year comparisons for Q3 FY26 are impossible due to missing data for Q3 FY25. Inconsistencies in 9-month financial table labeling were also noted, alongside a lack of forward-looking guidance.

📉 The Financial Deep Dive

Poly Medicure Limited announced its un-audited standalone and consolidated financial results for Q3 FY26, revealing significant sequential growth but hampered by missing year-on-year comparative data.

The Numbers:
Consolidated revenue for Q3 FY26 reached ₹11,886.15 lacs, marking an impressive 185.37% increase quarter-on-quarter (QoQ) from ₹4,165.42 lacs in Q2 FY26. Profit After Tax (PAT) followed suit, surging by 195.59% QoQ to ₹7,838.38 lacs from ₹2,651.76 lacs in the previous quarter. Basic EPS climbed to ₹7.73 from ₹2.43 QoQ. The company's PAT margin stood at a notable 65.95% for the quarter.

One-Offs & Quality:
An exceptional item of ₹680.40 lacs was recorded in Q3 FY26, attributed to past service costs for gratuity and compensated absences following the implementation of new Labour Codes. This impacted the reported profit for the period.

The Grill:
No management call transcript or specific analyst questions were provided in this filing. However, the absence of comparable YoY data for Q3 FY25 and inconsistencies in the labeling of nine-month periods in the financial tables present challenges for a comprehensive performance assessment. Furthermore, the company provided no forward-looking financial guidance or strategic outlook.

Strategic Developments:
The company is actively pursuing an inorganic growth strategy. Provisional accounting for the acquisitions of the Pendracare group and Medistream SA (Citieffe group) has been completed. The acquisition of Himalayan Mineral Water Private Limited has received NCLT approval but awaits further clarification from NCLAT. Proceeds from a Qualified Institutional Placement (QIP) completed in August 2024 are being utilized for capital expenditure, inorganic initiatives, and general corporate purposes. Additionally, 2,000 stock options were granted to eligible employees.

🚩 Risks & Outlook

The primary risks for Poly Medicure stem from the execution of its inorganic growth strategy, particularly potential delays or regulatory hurdles concerning the Himalayan Mineral Water acquisition. The lack of YoY comparative data for Q3 FY25 and labeling inconsistencies in the 9-month figures obscure a clear year-on-year performance trend. Investors will be looking for updated guidance and clarity on the integration and financial performance of the acquired entities in the coming quarters. The company operates in a single reportable segment: medical devices.

---

  • Consolidated Revenue (Q3 FY26): ₹11,886.15 lacs (+185.37% QoQ)

  • Consolidated PAT (Q3 FY26): ₹7,838.38 lacs (+195.59% QoQ)

  • Basic EPS (Q3 FY26): ₹7.73 (+219.75% QoQ)

  • PAT Margin (Q3 FY26): ~65.95%

  • Exceptional Item: ₹680.40 lacs (past service costs)

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.